Company profile
EQUILLIUM, INC.
NASDAQ:EQBiotechnology: Pharmaceutical Preparations
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07869225 | phase1 | not_yet_recruiting | 2026-10-01 | 2027-04-01 | Equillium | A Phase I, Randomized, Double-Blind, Placebo-Controlled Study of EQ504 in Single and Multiple Ascending Doses in Healthy Volunteers |
| NCT05263999 | phase3 | terminated | 2022-04-29 | 2025-04-22 | Equillium | A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR) |
| NCT03532958 | phase2 | withdrawn | 2021-10-01 | 2022-11-01 | Equillium | Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata |
| NCT05589610 | phase2 | completed | 2022-12-19 | 2024-03-26 | Equillium | Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata |
FDA applications (0)
No records yet.